Cytokines can counteract the inhibitory effect of MEK-i on NKcell function

Claudia Manzini, Roberta Venè, Irene Cossu, Marina Gualco, Simonetta Zupo, Mariella Dono, Francesco Spagnolo, Paola Queirolo, Lorenzo Moretta, Maria Cristina Mingari, Gabriella Pietra

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oncogene-targeted therapies based on mutated BRAF- and/or MEK-specific inhibitors have been developed for melanoma treatment. Although these drugs induce tumor regression in a high percentage of patients, clinical responses are frequently limited in time and tumors often recur. Recent studies suggested that the combination of BRAF/MEK inhibition with immunotherapy could represent a promising strategy for the cure of melanoma. NK cells are suitable effectors for tumor immunotherapy. Here we show that PLX4032 (a mutant BRAFV600 inhibitor) had no effect on the functional properties of NK cells cultured in the presence of IL-2 or IL-15. In contrast, PD0325901 (a MEK inhibitor) induced the down-regulation of the main activating NK receptors and inhibited NK cell function. Importantly, PD0325901 did not affect the anti-tumor activity of NK cells that had been exposed to a combination of IL-15 and IL-18. In addition, both PLX4032 and PD0325901 did not exert any inhibitory effect on in vitro IL-2 or IL-15 pre-activated NK cells. Our data may provide a rationale for future clinical protocols that combine IL- 15/IL-18 cytokine administration with MEK inhibitors. In addition, they suggest that oncogene-targeting drugs are compatible with NK-based adoptive therapy.

Original languageEnglish
Pages (from-to)60858-60871
Number of pages14
JournalOncotarget
Volume7
Issue number38
DOIs
Publication statusPublished - 2016

Fingerprint

Interleukin-15
Mitogen-Activated Protein Kinase Kinases
Natural Killer Cells
Cytokines
Interleukin-18
Oncogenes
Immunotherapy
Interleukin-2
Melanoma
Neoplasms
Natural Killer Cell Receptors
Drug Delivery Systems
Clinical Protocols
Therapeutics
Down-Regulation
Pharmaceutical Preparations
PD 0325901
PLX4032

Keywords

  • BRAF/MEK inhibitors
  • Cytokines
  • Immune response
  • Immunity
  • Immunology and Microbiology Section
  • Immunotherapy
  • Melanoma
  • NK cells

ASJC Scopus subject areas

  • Oncology

Cite this

Manzini, C., Venè, R., Cossu, I., Gualco, M., Zupo, S., Dono, M., ... Pietra, G. (2016). Cytokines can counteract the inhibitory effect of MEK-i on NKcell function. Oncotarget, 7(38), 60858-60871. https://doi.org/10.18632/oncotarget.11504

Cytokines can counteract the inhibitory effect of MEK-i on NKcell function. / Manzini, Claudia; Venè, Roberta; Cossu, Irene; Gualco, Marina; Zupo, Simonetta; Dono, Mariella; Spagnolo, Francesco; Queirolo, Paola; Moretta, Lorenzo; Mingari, Maria Cristina; Pietra, Gabriella.

In: Oncotarget, Vol. 7, No. 38, 2016, p. 60858-60871.

Research output: Contribution to journalArticle

Manzini, C, Venè, R, Cossu, I, Gualco, M, Zupo, S, Dono, M, Spagnolo, F, Queirolo, P, Moretta, L, Mingari, MC & Pietra, G 2016, 'Cytokines can counteract the inhibitory effect of MEK-i on NKcell function', Oncotarget, vol. 7, no. 38, pp. 60858-60871. https://doi.org/10.18632/oncotarget.11504
Manzini C, Venè R, Cossu I, Gualco M, Zupo S, Dono M et al. Cytokines can counteract the inhibitory effect of MEK-i on NKcell function. Oncotarget. 2016;7(38):60858-60871. https://doi.org/10.18632/oncotarget.11504
Manzini, Claudia ; Venè, Roberta ; Cossu, Irene ; Gualco, Marina ; Zupo, Simonetta ; Dono, Mariella ; Spagnolo, Francesco ; Queirolo, Paola ; Moretta, Lorenzo ; Mingari, Maria Cristina ; Pietra, Gabriella. / Cytokines can counteract the inhibitory effect of MEK-i on NKcell function. In: Oncotarget. 2016 ; Vol. 7, No. 38. pp. 60858-60871.
@article{799ec444e64d4e098ae7c36c6aaa781c,
title = "Cytokines can counteract the inhibitory effect of MEK-i on NKcell function",
abstract = "Oncogene-targeted therapies based on mutated BRAF- and/or MEK-specific inhibitors have been developed for melanoma treatment. Although these drugs induce tumor regression in a high percentage of patients, clinical responses are frequently limited in time and tumors often recur. Recent studies suggested that the combination of BRAF/MEK inhibition with immunotherapy could represent a promising strategy for the cure of melanoma. NK cells are suitable effectors for tumor immunotherapy. Here we show that PLX4032 (a mutant BRAFV600 inhibitor) had no effect on the functional properties of NK cells cultured in the presence of IL-2 or IL-15. In contrast, PD0325901 (a MEK inhibitor) induced the down-regulation of the main activating NK receptors and inhibited NK cell function. Importantly, PD0325901 did not affect the anti-tumor activity of NK cells that had been exposed to a combination of IL-15 and IL-18. In addition, both PLX4032 and PD0325901 did not exert any inhibitory effect on in vitro IL-2 or IL-15 pre-activated NK cells. Our data may provide a rationale for future clinical protocols that combine IL- 15/IL-18 cytokine administration with MEK inhibitors. In addition, they suggest that oncogene-targeting drugs are compatible with NK-based adoptive therapy.",
keywords = "BRAF/MEK inhibitors, Cytokines, Immune response, Immunity, Immunology and Microbiology Section, Immunotherapy, Melanoma, NK cells",
author = "Claudia Manzini and Roberta Ven{\`e} and Irene Cossu and Marina Gualco and Simonetta Zupo and Mariella Dono and Francesco Spagnolo and Paola Queirolo and Lorenzo Moretta and Mingari, {Maria Cristina} and Gabriella Pietra",
year = "2016",
doi = "10.18632/oncotarget.11504",
language = "English",
volume = "7",
pages = "60858--60871",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "38",

}

TY - JOUR

T1 - Cytokines can counteract the inhibitory effect of MEK-i on NKcell function

AU - Manzini, Claudia

AU - Venè, Roberta

AU - Cossu, Irene

AU - Gualco, Marina

AU - Zupo, Simonetta

AU - Dono, Mariella

AU - Spagnolo, Francesco

AU - Queirolo, Paola

AU - Moretta, Lorenzo

AU - Mingari, Maria Cristina

AU - Pietra, Gabriella

PY - 2016

Y1 - 2016

N2 - Oncogene-targeted therapies based on mutated BRAF- and/or MEK-specific inhibitors have been developed for melanoma treatment. Although these drugs induce tumor regression in a high percentage of patients, clinical responses are frequently limited in time and tumors often recur. Recent studies suggested that the combination of BRAF/MEK inhibition with immunotherapy could represent a promising strategy for the cure of melanoma. NK cells are suitable effectors for tumor immunotherapy. Here we show that PLX4032 (a mutant BRAFV600 inhibitor) had no effect on the functional properties of NK cells cultured in the presence of IL-2 or IL-15. In contrast, PD0325901 (a MEK inhibitor) induced the down-regulation of the main activating NK receptors and inhibited NK cell function. Importantly, PD0325901 did not affect the anti-tumor activity of NK cells that had been exposed to a combination of IL-15 and IL-18. In addition, both PLX4032 and PD0325901 did not exert any inhibitory effect on in vitro IL-2 or IL-15 pre-activated NK cells. Our data may provide a rationale for future clinical protocols that combine IL- 15/IL-18 cytokine administration with MEK inhibitors. In addition, they suggest that oncogene-targeting drugs are compatible with NK-based adoptive therapy.

AB - Oncogene-targeted therapies based on mutated BRAF- and/or MEK-specific inhibitors have been developed for melanoma treatment. Although these drugs induce tumor regression in a high percentage of patients, clinical responses are frequently limited in time and tumors often recur. Recent studies suggested that the combination of BRAF/MEK inhibition with immunotherapy could represent a promising strategy for the cure of melanoma. NK cells are suitable effectors for tumor immunotherapy. Here we show that PLX4032 (a mutant BRAFV600 inhibitor) had no effect on the functional properties of NK cells cultured in the presence of IL-2 or IL-15. In contrast, PD0325901 (a MEK inhibitor) induced the down-regulation of the main activating NK receptors and inhibited NK cell function. Importantly, PD0325901 did not affect the anti-tumor activity of NK cells that had been exposed to a combination of IL-15 and IL-18. In addition, both PLX4032 and PD0325901 did not exert any inhibitory effect on in vitro IL-2 or IL-15 pre-activated NK cells. Our data may provide a rationale for future clinical protocols that combine IL- 15/IL-18 cytokine administration with MEK inhibitors. In addition, they suggest that oncogene-targeting drugs are compatible with NK-based adoptive therapy.

KW - BRAF/MEK inhibitors

KW - Cytokines

KW - Immune response

KW - Immunity

KW - Immunology and Microbiology Section

KW - Immunotherapy

KW - Melanoma

KW - NK cells

UR - http://www.scopus.com/inward/record.url?scp=84992522061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992522061&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11504

DO - 10.18632/oncotarget.11504

M3 - Article

VL - 7

SP - 60858

EP - 60871

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 38

ER -